Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Hyperoside is natural product of the flavonoid class, found in Camptotheca acuminate, and has a variety of biological activities including antifungal, anti-oxidative, anti-inflammatory, anti-viral and anti-apoptotic activities. It acts by inhibiting HMGB1 signaling pathway and activating Nur77 receptor.
ln Vitro |
MCF-7 and 4T1 cell proliferation is inhibited by hyperin (12.5–100 μM; 6–24 h) [2]. In breast cancer cells, hypericin (25-100 μM; 24 h) produces fluoroscopy [2].
|
---|---|
ln Vivo |
The treatment of hypericin (intraperitoneal injection; 50 mg/kg; every two days for 18 days) reduces the growth of breast tumors in vivo [1].
|
Cell Assay |
Cell Viability Assay[2]
Cell Types: MCF-7 and 4T1 cells Tested Concentrations: 12.5, 25, 50, 75, or 100 µM Incubation Duration: 6, 12, The production of ROS inhibits the activation of NF-κB signaling dye[2]. or 24-hour Experimental Results: inhibition of cell growth in a time- and concentration-dependent manner. Apoptosis analysis[2] Cell Types: MCF-7 and 4T1 Cell Tested Concentrations: 25, 50 and 100 µM Incubation Duration: 24 hrs (hours) Experimental Results: Increased expression of Bax, cleaved caspase-3 and cleaved PARP in mRNA, diminished expression of Bcl-2 and protein levels. |
Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse injected with 4T1 cells [2]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; 50 mg/kg; once every two days for 18 days Experimental Results: Compared with the control group, the average tumor Volume reduction. Bcl-2 is diminished and bax and caspase-3 cleavage is increased. |
References |
[1]. Li S, et al. Antifungal activity of camptothecin, trifolin, and hyperoside isolated from Camptotheca acuminata. J Agric Food Chem. 2005 Jan 12;53(1):32-7.
[2]. Qiu J, et al. Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway. Int J Mol Sci. 2019 Dec 24;21(1):131. |
Molecular Formula |
C21H20O12
|
---|---|
Molecular Weight |
464.3763
|
Exact Mass |
464.09547607
|
CAS # |
482-36-0
|
Appearance |
Light yellow to yellow solid
|
SMILES |
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O
|
InChi Key |
OVSQVDMCBVZWGM-DTGCRPNFSA-N
|
InChi Code |
InChI=1S/C21H20O12/c22-6-13-15(27)17(29)18(30)21(32-13)33-20-16(28)14-11(26)4-8(23)5-12(14)31-19(20)7-1-2-9(24)10(25)3-7/h1-5,13,15,17-18,21-27,29-30H,6H2/t13-,15+,17+,18-,21+/m1/s1
|
Chemical Name |
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~125 mg/mL (~269.18 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10 mg/mL (21.53 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1534 mL | 10.7670 mL | 21.5341 mL | |
5 mM | 0.4307 mL | 2.1534 mL | 4.3068 mL | |
10 mM | 0.2153 mL | 1.0767 mL | 2.1534 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.